解剖病理学の世界市場-2023年～2030年

概要

世界の解剖病理学市場は2022年に167億米ドルに達し、2023-2030年の予測期間中にCAGR 8.3％で成長し、2030年には311億米ドルに達すると予測されています。

解剖病理学市場は、組織や細胞の検査を通じて疾病の診断と特徴を明らかにする上で重要な役割を果たしています。この市場には、がん、感染症、自己免疫疾患など、さまざまな疾患の特定と分析に使用される広範な臨床検査と技術が含まれます。解剖病理学サービスは、正確な疾病診断、予後予測、治療法の選択に不可欠であり、現代の医療システムにとって極めて重要な要素となっています。

世界の解剖病理学市場は、慢性疾患の有病率の増加、個別化医療に対する需要の高まり、診断技術の進歩、高齢化人口の増加、解剖病理学の技術的進歩・発展などの要因によって牽引されています。

ダイナミクス

個別化医療に対する需要の高まりが解剖病理学市場の成長を牽引

個別化医療は、遺伝子構成、バイオマーカー発現、疾患プロファイルなど、個人固有の特徴に基づいて医療治療や介入をカスタマイズすることを目的としています。解剖病理学は、個別化治療の決定を導くために必要な診断情報を提供する上で重要な役割を果たしています。病理医は組織や細胞のサンプルを分析し、特定のバイオマーカー、遺伝子変化、病理組織学的特徴を特定することで、個々の患者にとって最も効果的な治療法を決定します。

例えば、2023年3月、PathAIはNSCLCサンプル中のPD-L1陽性腫瘍細胞および免疫細胞を定量化するデジタル病理学プラットフォームであるAISightを発表しました。このプラットフォームは、PathAIの早期アクセスプログラムの一環として、米国の13の学術医療センター、リファレンスラボ、独立病理診断機関で使用されています。このプラットフォームは、世界中の患者のために精密医療を進歩させることを目的としています。

さらに、分子病理学技術は、個別化医療をサポートする解剖病理学の能力を大幅に向上させました。次世代シーケンシング、遺伝子発現プロファイリング、その他の分子診断により、特定の疾患に関連する遺伝子変異、遺伝子融合、その他の分子変化を同定することができます。これらの技術は、個人の疾患プロファイルを包括的に評価することを可能にし、標的療法の選択や個別化された治療計画を促進します。

慢性疾患の増加も解剖病理学市場の成長を促進する

解剖病理学は、がん、心血管疾患、神経疾患、自己免疫疾患などの様々な慢性疾患の診断とモニタリングにおいて重要な役割を果たしています。病理医は組織や細胞のサンプルを分析し、腫瘍の悪性度、病期分類、分子マーカーの有無など、特定の疾患特性を特定します。慢性疾患の正確な診断は、効果的な治療計画、疾病管理、治療の評価にとって不可欠です。

解剖病理学は診断技術の進歩の恩恵を受け、より正確で包括的な疾患評価を可能にしています。デジタル病理学や分子病理学などの技術革新は、慢性疾患を正確に診断する解剖病理学の能力を向上させました。これらの技術進歩により、疾患検出の感度と特異度が向上し、早期診断と治療成績の向上が可能になっています。

例えば2023年6月、アブダビ・ヘルス・サービス・カンパニー（SEHA）とメイヨー・クリニックの合弁事業であるシェイク・シャフバウト・メディカル・シティ（SSMC）は、解剖病理学研究所を開設しました。この先進的な施設は、専門家主導の病理学チームがAIを駆使したツールやアプリケーションを使って慢性疾患や複雑な症状を正確に診断するのを支援します。

熟練病理医の不足が市場の成長を妨げます。

熟練した病理医の不足は、特に解剖病理学サービスに対する需要の高まりに直面した場合、診断能力の限界につながる可能性があります。利用可能な病理医の数が限られているため、大量の症例を処理し、タイムリーな診断を提供する能力が損なわれる可能性があります。その結果、検査結果の納期が長くなり、患者の診断が遅れ、病理検査室に滞留する可能性があります。

熟練した病理医の不足は、解剖病理学サービスへのアクセスに影響を及ぼす可能性があります。患者はタイムリーで正確な診断サービスを受ける上で課題に直面し、治療方針の決定が遅れ、患者の転帰を損なう可能性があります。解剖病理学サービスへのアクセスが制限されると、患者の治療が妨げられ、市場の成長が阻害される可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 個別化医療に対する需要の高まり
    • 慢性疾患の増加
  • 抑制要因
    • 熟練病理医の不足
  • 機会
    • 診断技術の進歩
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析

第6章 COVID-19分析

第7章 製品・サービス別

• 消耗品
  • キット・試薬
  • 抗体
  • プローブ
  • その他
• 装置
  • ミクロトーム
  • 組織処理装置
  • 自動染色機
  • WSI (Whole Slide Imaging) システム
  • その他
• サービス

第8章 タイプ別

• 病理組織検査
• 細胞病理学
• 外科病理学
• その他

第9章 手法別

• 特殊染色
• 免疫組織化学
• 電子顕微鏡検査
• 遺伝子検査
• その他

第10章 応用分野別

• 疾病診断
• 創薬・医薬品開発

第11章 エンドユーザー別

• 病院
• 研究室
• 診断検査室
• その他

第12章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋
• 中東・アフリカ

第13章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第14章 企業プロファイル

• Quest Diagnostics Inc.
  • 企業概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な動向
• Danaher Corporation
• PHC Holdings Corporation
• Laboratory Corporation of America Holdings
• F. Hoffmann-La Roche AG
• Agilent Technologies Inc.
• Cardinal Health Inc.
• Sakura Finetek USA Inc.
• NeoGenomics Laboratories Inc.
• BioGenex

第15章 付録

Overview

Global anatomic pathology market reached US$ 16.7 billion in 2022 and is expected to reach US$ 31.1 billion by 2030 growing with a CAGR of 8.3% during the forecast period 2023-2030.

The anatomic pathology market plays a critical role in the diagnosis and characterization of diseases through the examination of tissues and cells. It encompasses a wide range of laboratory tests and techniques used to identify and analyze various diseases, including cancer, infectious diseases, and autoimmune disorders. Anatomic pathology services are essential for accurate disease diagnosis, prognosis, and treatment selection, making them a crucial component of modern healthcare systems.

The global anatomic pathology market is driven by the factors such as the increasing prevalence of chronic diseases, rising demand for personalized medicine, advancements in diagnostic technologies, rising aging population, and technological advancements and developments in anatomic pathology.

Dynamics

Rising Demand for Personalized Medicine Drives the Growth of the Anatomic Pathology Market

Personalized medicine aims to customize medical treatments and interventions based on an individual's unique characteristics, such as genetic makeup, biomarker expression, and disease profile. Anatomic pathology plays a vital role in providing the necessary diagnostic information to guide personalized treatment decisions. Pathologists analyze tissue and cell samples to identify specific biomarkers, genetic alterations, and histopathological features that help determine the most effective treatment options for individual patients.

For instance, in March 2023, PathAI launched AISight, a digital pathology platform that quantifies PD-L1 positive tumor and immune cells in NSCLC samples. The platform is used in 13 academic medical centers, reference laboratories, and independent pathology organizations in the US as part of PathAI's Early Access Program. The platform aims to advance precision medicine for patients worldwide.

Moreover, Molecular pathology techniques have significantly advanced the capabilities of anatomic pathology in supporting personalized medicine. Next-generation sequencing, gene expression profiling, and other molecular diagnostics enable the identification of genetic mutations, gene fusions, and other molecular alterations associated with specific diseases. These technologies allow for a comprehensive assessment of an individual's disease profile, facilitating the selection of targeted therapies and personalized treatment plans.

Increasing Prevalence of Chronic Diseases Also Drives the Growth of the Anatomic Pathology Market

Anatomic pathology plays a crucial role in the diagnosis and monitoring of various chronic diseases such as cancer, cardiovascular diseases, neurological disorders, and autoimmune conditions. Pathologists analyze tissue and cell samples to identify specific disease characteristics, including tumor grading, staging, and the presence of molecular markers. Accurate diagnosis of chronic diseases is essential for effective treatment planning, disease management, and assessing treatment.

Anatomic pathology benefited from advancements in diagnostic techniques, enabling more precise and comprehensive disease assessment. The innovations such as digital pathology, and molecular pathology enhanced the capabilities of anatomic pathology to accurately diagnose chronic diseases. These technological advancements have improved the sensitivity and specificity of disease detection, allowing for early diagnosis and better treatment outcomes.

For instance, in June 2023, Sheikh Shakhbout Medical City (SSMC), a joint venture between Abu Dhabi Health Services Company (SEHA) and Mayo Clinic, launched an Anatomical Pathology Laboratory. This advanced facility will aid the expert-led pathology team in accurately diagnosing chronic diseases and complex conditions using AI-powered tools and applications.

A Lack of Skilled Pathologists Will Hamper the Growth of the Market.

A lack of skilled pathologists can result in limited diagnostic capacity, especially when faced with a growing demand for anatomic pathology services. With a limited of pathologists available, the capacity to handle a larger volume of cases and deliver timely diagnoses may be compromised. This can lead to longer turnaround times for test results, delayed patient diagnoses, and potential backlogs in pathology laboratories.

A lack of skilled pathologists can impact access to anatomic pathology services. Patients face challenges in accessing timely and accurate diagnostic services, leading to delays in treatment decisions and potentially compromising patient outcomes. Limited access to anatomic pathology services can hinder the growth of the market by impeding patient care.

Segment Analysis

The global anatomic pathology market is segmented based on product and services, type, technique, application, end-user, and region.

The Consumables Segment Accounted for Approximately 36.3% of the Anatomic Pathology Market Share

Consumables are essential components used in various laboratory processes within anatomic pathology, including sample collection, processing, staining, and analysis. These consumables include slides, reagents, stains, antibodies, and other materials required for sample preparation and testing. As anatomic pathology services are constantly in demand for disease diagnosis and monitoring, there is a continuous need for consumables, driving their dominance in the market.

For instance, on June 2023, StatLab Medical Products (StatLab), a leading global developer and manufacturer of medical diagnostic equipment and supplies, is expanding across multiple manufacturing sites to support business growth after the successful acquisition of two UK-based histology consumables and diagnostic equipment companies.

Anatomic pathology involves a high volume of routine and repetitive testing, particularly in cancer diagnostics. Routine procedures such as histology, cytology, and immunohistochemistry require consumables for processing large numbers of samples. The repetitive nature of these procedures leads to higher consumption of consumables, contributing to their significant market share.

For instance, in April 2023, Xyall and Indica Labs entered into a global strategic partnership designed to bridge the gap between histology and molecular pathology. It unites Xyall's unique automated tissue dissection solutions with Indica Labs' AI-powered, diagnostic digital pathology platform.

Geographical Penetration

North America Accounted for Approximately 39.6% of the Market Share in 2022, Owing to the Advanced Healthcare Infrastructure and Technological Advancements

North America has a well-established and advanced healthcare infrastructure, which includes state-of-the-art diagnostic facilities and pathology laboratories. The region has a high concentration of renowned academic institutions, research centers, and medical schools that drive innovation in anatomic pathology. The availability of skilled pathologists, and robust healthcare systems contribute to the growth and dominance of the market in North America.

North America is at the forefront of technological advancements in anatomic pathology. The region has been quick to adopt and integrate digital pathology and AI technologies into diagnostic workflows. The utilization of these advanced technologies enhances efficiency, accuracy, and productivity in anatomic pathology services. North American companies and research institutions lead in developing and commercializing innovative diagnostic technologies, further strengthening the market's dominance in the region.

For instance, in March 2023, OptraSCAN, the leading end-to-end digital pathology solution provider announces the introduction of the OnDemand Digital Pathology solution to meet today's need for the complete digital transformation of pathology laboratories in North America. Laboratories and Hospitals can save hundreds of thousands of dollars spent on Capital purchases by subscribing to OptraSCAN OnDemand Digital Pathology for a low monthly fee.

Competitive Landscape

The major global players in the anatomic pathology market include Quest Diagnostics Inc., Danaher Corporation, PHC Holdings Corporation, Laboratory Corporation of America Holdings, F. Hoffmann-La Roche AG, Agilent Technologies Inc., Cardinal Health Inc., Sakura Finetek USA Inc., NeoGenomics Laboratories Inc., and BioGenex.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global anatomic pathology market. The pandemic led to a shift in diagnostic priorities, with a heightened focus on COVID-19 testing. Anatomic pathology laboratories had to adapt their operations to accommodate the increased demand for COVID-19 testing, including the processing of respiratory samples and performing molecular tests like PCR. This shift in focus resulted in a diversion of resources and workforce from other diagnostic areas, potentially impacting the volume of non-COVID-19 related tests.

ussia Ukraine Conflict Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global anatomic pathology market. The conflict can disrupt the global supply chains of laboratory equipment, reagents, and consumables used in anatomic pathology. Both Russia and Ukraine are major producers and suppliers of medical devices and laboratory products. Any disruption in the production, distribution, or transportation of these supplies leads to shortages and increased costs for anatomic pathology laboratories worldwide.

By Product & Services

• Consumables

Kits & Reagents

Antibodies

Probes

Others

• Instruments

Microtomes

Tissue Processors

Automatic Stainers

Whole Slide Imaging (WSI) Systems

Others

• Services

By Type

• Histopathology
• Cytopathology
• Surgical Pathology
• Others

By Technique

• Special Staining
• Immunohistochemistry
• Electron Microscopy
• Genetic Testing
• Others

By Application

• Disease Diagnosis
• Drug Discovery and Development
• Others

By End User

• Hospitals
• Research Laboratories
• Diagnostic Laboratories
• Others

By Region

• North America

U.S.

Canada

Mexico

• Europe

Germany

U.K.

France

Spain

Italy

Rest of Europe

• South America

Brazil

Argentina

Rest of South America

• Asia-Pacific

China

India

Japan

Australia

Rest of Asia-Pacific

• Middle East and Africa

Key Developments

• On April 17, 2023, Xyall and Indica Labs entered into a global strategic partnership designed to bridge the gap between histology and molecular pathology. The partnership enables Xyall's industry-leading automated Tissector tissue dissection solutions to capitalize on Indica Labs' flagship HALO AP anatomic pathology image management and workflow software, which facilitates primary diagnosis, remote slide review, case sign-out, and more.
• On April 10, 2023, Versant Diagnostics, an independent physician services company, announced a joint collaboration agreement with In-Office Pathology, LLC (IOP), a Nantucket-based specialist in building in-office laboratories, to increase access to pathologists and build pathology labs in an evolving industry. Versant Diagnostics will offer anatomic pathology services to IOP's network of in-office labs, and IOP will build laboratories at select Versant Diagnostics specialty clinics and physician practices.
• On September 23, 2022, Epredia, a global leader in precision cancer diagnostics, announces that its parent company PHC Holdings Corporation has acquired the anatomical pathology equipment suppliers, Microm Microtech France (MM France) and Laurypath, as part of a strategic expansion of Epredia's presence in Europe.

Why Purchase the Report?

• To visualize the global anatomic pathology market segmentation based on product & services, type, technique, application, end-user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of anatomic pathology market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global anatomic pathology market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product & Services
• 3.2. Snippet by Type
• 3.3. Snippet by Technique
• 3.4. Snippet by Application
• 3.5. Snippet by End-User
• 3.6. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising Demand for Personalized Medicine
    • 4.1.1.2. Increasing Prevalence of Chronic Diseases
  • 4.1.2. Restraints
    • 4.1.2.1. Lack of Skilled Pathologists
  • 4.1.3. Opportunity
    • 4.1.3.1. Advancements in Diagnostic Techniques
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Scenario Post COVID-19
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Product & Services

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product & Services
  • 7.1.2. Market Attractiveness Index, By Product & Services
• 7.2. Consumables *
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.2.3. Kits & Reagents
  • 7.2.4. Antibodies
  • 7.2.5. Probes
  • 7.2.6. Others
• 7.3. Instruments
  • 7.3.1. Microtomes
  • 7.3.2. Tissue Processors
  • 7.3.3. Automatic Stainers
  • 7.3.4. Whole Slide Imaging (WSI) Systems
  • 7.3.5. Others
• 7.4. Services

8. By Type

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 8.1.2. Market Attractiveness Index, By Type
• 8.2. Histopathology *
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Cytopathology
• 8.4. Surgical Pathology
• 8.5. Others

9. By Technique

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique
  • 9.1.2. Market Attractiveness Index, By Technique
• 9.2. Special Staining *
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Immunohistochemistry
• 9.4. Electron Microscopy
• 9.5. Genetic Testing
• 9.6. Others

10. By Application

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.1.2. Market Attractiveness Index, By Application
• 10.2. Disease Diagnosis *
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Drug Discovery and Development

11. By End-User

• 11.1. Introduction
  • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.1.2. Market Attractiveness Index, By End-User
• 11.2. Hospitals *
  • 11.2.1. Introduction
  • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 11.3. Research Laboratories
• 11.4. Diagnostic Laboratories
• 11.5. Others

12. By Region

• 12.1. Introduction
  • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 12.1.2. Market Attractiveness Index, By Region
• 12.2. North America
  • 12.2.1. Introduction
  • 12.2.2. Key Region-Specific Dynamics
  • 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product & Services
  • 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique
  • 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 12.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.2.8.1. U.S.
    • 12.2.8.2. Canada
    • 12.2.8.3. Mexico
• 12.3. Europe
  • 12.3.1. Introduction
  • 12.3.2. Key Region-Specific Dynamics
  • 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product & Services
  • 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique
  • 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 12.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.3.8.1. Germany
    • 12.3.8.2. U.K.
    • 12.3.8.3. France
    • 12.3.8.4. Spain
    • 12.3.8.5. Italy
    • 12.3.8.6. Rest of Europe
• 12.4. South America
  • 12.4.1. Introduction
  • 12.4.2. Key Region-Specific Dynamics
  • 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product & Services
  • 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique
  • 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 12.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 12.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.4.8.1. Brazil
    • 12.4.8.2. Argentina
    • 12.4.8.3. Rest of South America
• 12.5. Asia-Pacific
  • 12.5.1. Introduction
  • 12.5.2. Key Region-Specific Dynamics
  • 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product & Services
  • 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique
  • 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 12.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 12.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.5.8.1. China
    • 12.5.8.2. India
    • 12.5.8.3. Japan
    • 12.5.8.4. Australia
    • 12.5.8.5. Rest of Asia-Pacific
• 12.6. Middle East and Africa
  • 12.6.1. Introduction
  • 12.6.2. Key Region-Specific Dynamics
  • 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product & Services
  • 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique
  • 12.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 12.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

13. Competitive Landscape

• 13.1. Competitive Scenario
• 13.2. Market Positioning/Share Analysis
• 13.3. Mergers and Acquisitions Analysis

14. Company Profiles

• 14.1. Quest Diagnostics Inc. *
  • 14.1.1. Company Overview
  • 14.1.2. Product Portfolio and Description
  • 14.1.3. Financial Overview
  • 14.1.4. Key Developments
• 14.2. Danaher Corporation
• 14.3. PHC Holdings Corporation
• 14.4. Laboratory Corporation of America Holdings
• 14.5. F. Hoffmann-La Roche AG
• 14.6. Agilent Technologies Inc.
• 14.7. Cardinal Health Inc.
• 14.8. Sakura Finetek USA Inc.
• 14.9. NeoGenomics Laboratories Inc.
• 14.10. BioGenex

LIST NOT EXHAUSTIVE

15. Appendix

• 15.1. About Us and Services
• 15.2. Contact Us